Clinical Trials Browser

Recruiting × Blastic Plasmacytoid Dendritic Cell Neoplasm × Clear all

NCT04216524 2026-03-04

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 2 Recruiting

40 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT05430971 2026-02-17

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Recruiting

200 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT05362773 2026-01-13

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1 Recruiting

130 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT06765876 2026-01-12

UHKT-CAR123-01

Phase EARLY_PHASE1 Recruiting

18 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03113643 2025-11-04

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1 Recruiting

72 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04318678 2025-10-23

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Phase 1 Recruiting

108 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03779854 2025-10-15

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Phase 2 Recruiting

68 enrolled

LymphoidMyeloidOther hematologic neoplasm

GATA2 Deficiency, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Mast-Cell, Leukemia, Myeloid, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Phase 1 Recruiting

46 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmSarcoma

Blastic Plasmacytoid Dendritic Cell Neoplasm, Histiocytosis, Langerhans-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Erdheim-Chester Disease, Dendritic Cell Sarcoma, Interdigitating, Histiocytic Sarcoma, Primary Myelofibrosis

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Phase 1 Recruiting

54 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06690827 2024-11-15

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Phase 1 Recruiting

30 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT06006403 2023-08-30

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 1/2 Recruiting

36 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute